

<b>Enclosure No:</b>	7/AWMSG/1216
<b>Agenda item No:</b>	11 – Dry Eye Syndrome Guidance
<b>Author:</b>	All Wales Therapeutics and Toxicology Centre
<b>Contact:</b>	Tel: 02920 71 6900 <a href="mailto:awttc@wales.nhs.uk">awttc@wales.nhs.uk</a>

## 1.0 ACTION FOR AWMSG

All Wales Medicines Strategy Group (AWMSG) members are requested to consider the Dry Eye Syndrome Guidance document for endorsement.

## 2.0 PURPOSE

The cost of dry eye syndrome treatments for the NHS in Wales is approximately £3.4 million annually. Some health boards have developed guidance on a stepped care approach to prescribing for dry eye syndrome. This guidance usually includes eye treatment options, but not always detailed information around patient self-care. It is apparent that across Wales, there could be a more consistent approach to prescribing and the provision of self-care advice, and it is proposed that a prudent approach is taken to treating dry eye syndrome in Wales. This guidance therefore aims to:

- provide information to healthcare professionals so that they can better inform patients on how to manage their condition;
- aid healthcare professionals in prescribing;
- reduce spend on dry eye products.

This guidance will be used by healthcare professionals in a primary or secondary care setting, including pharmacists, optometrists, GPs, ophthalmologists and other hospital doctors (such as rheumatologists). It may be possible to develop multidisciplinary audit templates to support implementation. The Wales Centre for Pharmacy Professional Education (WCPPE), Wales Optometry Postgraduate Education Centre (WOPEC), and Wales Deanery may be able to develop a joint e-learning package to support this Dry Eye Syndrome Guidance. One way in which reductions in spend and volume, and compliance with the recommended products could be measured is by monitoring prescribing cost and items for dry eye products (data for the number of prescriptions and prescribing cost will be provided by the NHS Wales Shared Services Partnership [NWSSP] to allow trends in volume, cost and product mix to be tracked over time).

This project is pertinent to AWMSG recommendations 2, 4, 6 and 8 from the [AWMSG Five-year Strategy 2013–2018](#):

- **Improving health – Prescribing guidance** – AWMSG will work with health boards and other stakeholders to promote the safe, effective and cost-effective use of medicines in Wales.
- **Fully integrated network of care** – AWMSG will work with stakeholders so that care can be delivered in the most appropriate setting.
- **Transparency of performance** – AWMSG will conduct its work in an open and transparent manner.
- **Making every penny count** – AWMSG will work with NHS Wales and the people of Wales to promote better value prescribing and reduce inappropriate prescribing by providing high quality advice on prudent prescribing in general practice, hospitals and the community.

## DRAFT FOR AWMSG ENDORSEMENT

### 2.1 Process

- Project considered by AWTTTC New Projects Group 10 June 2016
- Project proposal presented to AWMSG Steering Committee 21 June 2016
- Draft guidance to AWPAG meeting 22 June 2016
- Draft guidance to Consultation 25 August 2016–12 September 2016
- Draft guidance to AWPAG meeting 28 September 2016
- Draft guidance to AWMSG Steering Committee 22 November 2016
- Guidance to AWMSG meeting 7 December 2016
- *Review date 3 years*

### 2.2 Stakeholders

- Optometrists
- Ophthalmologists
- GPs
- Hospital doctors (e.g. rheumatologists)
- Pharmacists
- Clinical Lead for Eye Health Examination Wales (EHEW)
- Chief Optometric Advisor
- Eye care professional groups
- Chair Ophthalmology Specialist Advisory Group
- Health board prescribing advisory teams
- Welsh representative for the Royal College of Ophthalmology
- Chair of Wales Optometric Committee

### 3.0 SUMMARY

Dry eye syndrome is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface<sup>1</sup>. By taking suitable precautions, the symptoms of dry eye can be lessened and, in mild cases, this may be sufficient to avoid the need for treatment. This document contains information on self-management, as well as prescribing guidelines and guidance on when referral should be made. It is envisaged that this guidance will result in cost savings to NHS Wales, a more consistent approach across Wales to the prescribing of dry eye syndrome treatments and the provision of self-care advice, and improved understanding of dry eye syndrome by healthcare professionals and patients.

## DRAFT FOR AWMSG ENDORSEMENT

### CONTENTS

1.0 SUMMARY .....	4
2.0 DRY EYE SYNDROME .....	5
2.1 Evaporative dry eye .....	5
2.2 Aqueous tear-deficient dry eye .....	5
3.0 REFERRAL .....	6
4.0 MANAGEMENT OF DRY EYE SYNDROME .....	6
4.1 Patient self-management .....	7
4.1.1 Good eyelid hygiene.....	7
4.1.2 Applying eye drops.....	8
4.2 Prescribing guidelines.....	8
4.3 Severe symptoms .....	9
4.4 Preservative toxicity from eye lubricants .....	10
4.5 Eye drop dispensers .....	10
5.0 FURTHER RESOURCES.....	10
REFERENCES.....	11

## DRAFT FOR AWMSG ENDORSEMENT

### 1.0 SUMMARY

Dry eye syndrome is a chronic condition, loosely categorised as:

- Evaporative dry eye (EDE) – the most common form of dry eye syndrome, often associated with increased evaporation and an unstable tear film<sup>1</sup>. Meibomian gland dysfunction (MGD) is thought to be the leading cause of EDE<sup>2,3</sup>.
- Aqueous tear-deficient dry eye (ADDE) – refers chiefly to a failure of lacrimal tear secretion<sup>1</sup>.

People with dry eye syndrome typically present with<sup>4</sup>:

- feelings of dryness, grittiness, or soreness in both eyes, which worsen through the day; watering of the eyes, particularly when exposed to wind; no abnormalities on examination.

By taking suitable precautions, patients can lessen the symptoms of dry eye and, in mild cases, this may be sufficient to avoid the need for treatment. Precautions include:

- maintaining good eyelid hygiene. Eyelids should be cleaned in a stepwise manner twice-daily initially, then once-daily as symptoms improve<sup>5</sup>:
  - apply a warm compress to closed eyelids for 5–10 minutes;
  - massage closed eyelids in a circular motion across the length of each lid;
  - to clean the eyelid, wet a cloth/cotton wool pad with cleaner and wipe along the lid margins;
- limiting contact lens use to shorter periods, especially if these cause irritation<sup>4</sup>;
- stopping smoking<sup>4</sup>;
- using a humidifier to moisten ambient air<sup>4</sup>, and avoiding prolonged periods in air-conditioned environments;
- if using a computer for long periods, placing the monitor at or below eye level, avoiding staring at the screen, and taking frequent breaks<sup>4</sup>;
- avoiding makeup<sup>5</sup>.

All dry eye syndrome treatments should be offered in conjunction with advice on appropriate self-management.

**Table 1. Summary of prioritised treatment options for the management of dry eye**

First-line treatment*		
Hypromellose	Carbomers	Polyvinyl alcohol
<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>
Appropriate for the majority with mild dry eye. May need to be instilled at 60-minute intervals until symptoms improve, then at a decreased frequency	Require less frequent administration but may be less well tolerated than hypromellose	
+/- liquid paraffin at night		
If failure to improve symptoms after 6 to 8 weeks, progress to second-line treatment options		
Second-line treatment*		
Hydroxypropyl guar	Carmellose sodium	Sodium hyaluronate
<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>
		No evidence to support differences in efficacy between different strengths, although the different dropper systems may affect patient acceptability <sup>6</sup>
+/- liquid paraffin at night		
If failure to improve symptoms after 6 to 8 weeks, refer for specialist input		

To insert health board choices, please request a Word version of this document from [awtc@wales.nhs.uk](mailto:awtc@wales.nhs.uk).

\*Combination treatment options are available; these should be considered on an individual patient basis

### 2.0 DRY EYE SYNDROME

Dry eye syndrome is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface<sup>1</sup>.

Dry eye syndrome is a common condition, having an increasing prevalence with increasing age. It is about 50% more common in women than in men<sup>4</sup>. People with dry eye syndrome typically present with<sup>4</sup>:

- feelings of dryness, grittiness, or soreness in both eyes, which worsen through the day;
- watering of the eyes, particularly when exposed to wind;
- no abnormalities on examination.

Less commonly, people present with a complication of dry eye syndrome, for example conjunctivitis<sup>4</sup>.

Dry eye syndrome is loosely categorised as evaporative dry eye (EDE) or aqueous tear-deficient dry eye (ADDE). Both of these conditions may be seen in patients with dry eye syndrome<sup>7</sup>.

#### 2.1 Evaporative dry eye

EDE is the most common form of dry eye and is often associated with deficiency of the lipid layer of the tear film, leading to increased evaporation and an unstable tear film<sup>1</sup>. As it is an evaporative condition, symptoms get worse throughout the day.

Meibomian gland dysfunction (MGD) is thought to be the leading cause of EDE and may also have some association with ADDE<sup>3</sup>; it is important to note that the clinical symptoms of MGD overlap with those of other types of EDE, as well as those of ADDE<sup>8,9</sup>. MGD is a chronic abnormality of the meibomian glands, commonly characterised by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion. It may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease<sup>8</sup>.

Posterior blepharitis is a term often used interchangeably with MGD, but they are not synonymous; posterior blepharitis affects the inner edge of the eyelid and is only one possible cause of MGD<sup>8</sup>.

When the lipid layer is poor, the tear film becomes particularly vulnerable to:

- environmental factors, such as windy conditions and low humidity, e.g. air conditioning<sup>10</sup>;
- low blink rate/wide lid aperture (e.g. prolonged reading/use of a computer)<sup>4,11</sup>. Patients may complain of intermittent blurring of vision or discomfort after short periods of reading<sup>10</sup>.

#### 2.2 Aqueous tear-deficient dry eye

ADDE refers chiefly to a failure of lacrimal tear secretion. However, a failure of water secretion by the conjunctiva could also contribute to ADDE<sup>1</sup>. Patients often complain of a worsening of their symptoms towards the evening<sup>10</sup>.

ADDE can be associated with non-autoimmune causes, including some medications<sup>12</sup>, lacrimal deficiency, lacrimal gland duct obstruction, and reflex block<sup>1,10</sup>. ADDE can also be associated with autoimmune diseases, e.g. rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus<sup>10</sup>.

### 3.0 REFERRAL

Referral to a specialist should be considered in patients with signs of corneal damage such as ulcers, or other secondary complications (e.g. vascularisation, melt, infection). Symptoms such as moderate to severe eye pain or photophobia, marked redness in one eye and reduced visual acuity could be due to other potential severe eye conditions such as acute glaucoma, keratitis and iritis. The potential for sight-threatening complications is high and so same-day referral should be made<sup>4</sup>. In most circumstances, it is usually appropriate to advise people to see an optometrist before an ophthalmologist<sup>4</sup>. Those people who have an eye problem requiring urgent attention can be referred by a healthcare professional to an optometrist to have an eye examination at an [Eye Health Examination Wales \(EHEW\) accredited optometrist practice](#).

Associated diseases of dry eye syndrome require other specialist management<sup>4</sup> (e.g. rheumatology for Sjögren's syndrome, or oculoplastics for eyelid deformities). Blepharokeratitis in children is a serious and potentially blinding disease. Urgent referral to an ophthalmologist is required for children with any corneal change (e.g. staining or vascularisation).

Referral to an optometrist should also be made, or advice from an optometrist should be obtained, if<sup>†</sup>:

- symptoms are not suitably controlled despite appropriate treatment for about 4 weeks;
- diagnosis requires specialist assessment (apply a lower threshold for obtaining specialist advice for younger people);
- vision deteriorates<sup>4</sup>.

The EHEW accredited optometrist scheme is available in most parts of Wales. An optometrist can assess people with dry eye syndrome and advise on treatment. A list of EHEW accredited optometrist practices, as well as details on how optometrists and ophthalmic medical practitioners can register for EHEW accreditation, is available [here](#).

### 4.0 MANAGEMENT OF DRY EYE SYNDROME

Those people with an apparent eye-related problem can be referred by a healthcare professional to have a free eye health examination at an EHEW accredited optometrist practice. Some optometrist practices offer private specialist dry eye clinics of varying service levels<sup>7</sup>. Patients should be informed that it is likely that these clinics will need to be self-funded.

Contact lens wearers presenting with dry eye syndrome should be encouraged to attend their prescribing optometrist<sup>10</sup>, as symptoms may be managed by changing the lens replacement frequency or material.

As MGD and posterior blepharitis are chronic conditions, it is important that patients are aware that they can be prone to exacerbations<sup>5,8</sup>. As a result, these conditions require long-term management and likely treatment, which can lessen the impact of the condition but will not cure it. Ongoing active patient involvement and self-management are therefore essential.

Disease severity should not be based upon symptoms alone as they can be a relatively poor indicator. Currently, there is no gold standard test for determining dry eye disease severity<sup>2</sup>.

---

<sup>†</sup>Consider referral to an optometrist if a preservative-free topical eye product is required for more than 4 weeks<sup>4</sup>

### 4.1 Patient self-management

Advise patients that by taking suitable precautions, the symptoms of dry eye syndrome can be lessened and, in mild cases, this may be sufficient to avoid the need for treatment<sup>4</sup>. These precautions include:

- ensuring that the patient has good eyelid hygiene to control posterior blepharitis or MGD<sup>8</sup> (see section 4.1.1);
- limiting contact lens use to shorter periods, especially if these cause irritation<sup>4</sup>;
- highlighting the effect of cigarette smoke on dry eyes and encouraging the patient to stop smoking<sup>4</sup>. Patients can be directed to call 'Stop Smoking Wales' free on 0800 085 2219;
- suggesting use of a humidifier to moisten ambient air<sup>4</sup>, and avoiding prolonged periods in air-conditioned environments;
- if using a computer for long periods, suggesting that the patient places their monitor at or below eye level, avoids staring at the screen, and takes frequent breaks<sup>4</sup>.

There is some evidence to suggest that eating a healthy, balanced diet high in omega-3 fatty acids (e.g. oily fish, various nuts and seeds, vegetable oils, soya and soya products) can help improve dry eye syndrome<sup>11</sup>. Some groups of people should be careful about the amount of oily fish in their diet, or omega-3 supplements (e.g. pregnant women), so the patient should check with their doctor or pharmacist<sup>13</sup>.

#### 4.1.1 Good eyelid hygiene

Some patients may find it difficult to perform lid hygiene properly; therefore, detailed instruction should be given to all patients (further patient information can be found in section 5.0). Advise the patient that their eyelids should be cleaned in a stepwise manner twice-daily initially, then once-daily as symptoms improve<sup>5</sup>:

- Apply a warm compress to closed eyelids for 5–10 minutes. The compress can be a clean cloth warmed in hot water<sup>5</sup>. Advise the patient not to use a compress that is too hot as it may burn the skin, although current research indicates that compression temperatures of less than 40°C applied for less than 5 minutes are ineffective<sup>14</sup>. A warm compress will not retain sufficient heat, so patients should be reminded to reheat frequently. Commercial devices are available and may be used instead<sup>15</sup>. Patients should be informed that these will need to be self-funded.
- Following application of the compress, the patient should massage the closed eyelid in a circular motion across the length of each lid: this aids expression of meibomian gland secretions<sup>5,11</sup>.
- To clean the eyelid, the patient should wet a cloth or cotton wool pad with cleanser (for example, baby shampoo diluted 1:10 with warm water) and wipe along the lid margins. The overall aim is gentle mechanical washing, which clears the debris and therefore reduces inflammation of the eyelid margin. There are commercial eyelid cleansing solutions available<sup>5</sup>.
- Advise the patient to avoid eye make-up, especially eyeliner. If this is not possible, advise the patient to use one that washes off easily<sup>5</sup> and to replace make-up products regularly.
- Contact lenses should not be worn during the eyelid hygiene procedure. Use should be limited in dry eye, especially if they cause irritation<sup>4</sup>.
- If there are signs of staphylococcal infection, eyelid scrubs/wipes can be used to wipe away the scales on the lashes<sup>§</sup>.

---

<sup>§</sup>Commercial devices are available which reduce scurf and bacterial debris and improve the overall health of the eyelid. Scurf and bacterial debris are the main causes of inflammatory lid disease.

## DRAFT FOR AWMSG ENDORSEMENT

### 4.1.2 Applying eye drops

Patients should be advised to:

- wash their hands before and after using eye drops<sup>16</sup>;
- administer eye drops on the side of the eye nearest the ear by pulling down the lid to form a sac<sup>16</sup>. To reduce contamination of the bottle, patients should avoid touching the ocular surface with the nozzle<sup>7</sup>.

If dry eye products are used in conjunction with other eye preparations, a time interval of around 5 minutes between applications should be advised, with the more viscous product being applied last<sup>7</sup>.

### 4.2 Prescribing guidelines

Generic treatments, including lubricants, oily tear drops and eye ointments, selected in a prioritised manner may be prescribed to people with dry eye syndrome. These generic eye treatments do not however treat the root cause of MGD as they do not loosen blockages in the meibomian glands<sup>9</sup>. Therefore, eye drops should be used in conjunction with self-management methods.

A dry eye syndrome treatment should be tried for 4–6 weeks before assessing benefit<sup>10</sup>. It is suggested that patients are tried on treatments in a prioritised manner, as suggested within Table 2; this will allow selection and confirmation of the most appropriate dry eye treatment option for the patient. The patient should be encouraged to provide feedback on how their symptoms are progressing. This will facilitate a selection based upon their individual needs, thus satisfying the core elements of prudent healthcare, whilst optimising use of available resources.

Once symptoms are controlled, if the patient's maintenance regimen is greater than 4–6 times a day, a review of the dry eye treatment may be needed with consideration of alternative or additional options<sup>17</sup>.

Patients who struggle to apply their eye drops (e.g. as a result of arthritis) may benefit from changing to a different type of product; some dispensers may be easier to use than others<sup>7</sup>.

**Table 2. Prioritised treatment options for the management of dry eye syndrome<sup>¶</sup>**

First-line treatment <sup>*</sup>		
Hypromellose	Carbomers	Polyvinyl alcohol
<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>
If failure to improve symptoms after 6 to 8 weeks, progress to second-line treatment options		
Second-line treatment <sup>*</sup>		
Hydroxypropyl guar	Carmellose sodium	Sodium hyaluronate
<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>	<i>Insert health board choice(s):</i>
If failure to improve symptoms after 6 to 8 weeks, refer for specialist input		
Ophthalmologist-initiation only		
<b>Acetylcysteine 5% eye drops</b>	<b>Ciclosporin 1 mg/ml eye drops</b>	

To insert health board choices, please request a Word version of this document from [awttc@wales.nhs.uk](mailto:awttc@wales.nhs.uk).

<sup>¶</sup>With the exception of acetylcysteine and ciclosporin, most treatment options are available without a prescription

<sup>\*</sup>Combination treatment options are available; these should be considered on an individual patient basis

## DRAFT FOR AWMSG ENDORSEMENT

The majority of patients in primary care can be managed with first-line agents. Hypromellose is the traditional choice of treatment for tear deficiency and should be appropriate for the majority of patients presenting with mild dry eye. Hypromellose eye drops may need to be instilled frequently (at 60-minute intervals)<sup>18</sup> initially until symptoms improve, then applied at a decreased frequency.

Dry eye syndrome treatments containing carbomers or polyvinyl alcohol require less frequent administration but may be less well tolerated than hypromellose<sup>2</sup>. A balance of longer retention time versus impact on vision should be addressed. Formulations containing wetting agents to retain moisture may be effective in managing symptoms. Within a first-line regimen, using both hypromellose and carbomers may be appropriate to try before progressing to second-line treatment options.

Consider adding the ocular lubricant liquid paraffin within first-line and second-line treatment regimens, if appropriate. Patients with ADDE often benefit from the use of a liquid paraffin ointment at night. However, eye ointments containing paraffin may be uncomfortable and blur vision, so they should not be used during the day and never with contact lenses<sup>4</sup>. Transient blurring can also be a problem with more viscous drops<sup>10</sup>.

Lubricants containing sodium hyaluronate, hydroxypropyl guar, or lipid-containing drops may be used for moderate to severe dry eye disease following a suitable trial of first-line agents. There is no evidence to support any differences in efficacy between the different strengths available for sodium hyaluronate, although the different delivery systems of the products may affect patient acceptability<sup>6</sup>. Some sodium hyaluronate delivery systems give longer in-use expiry dates<sup>6</sup>. If required, these should be considered on an individual patient basis.

A large range of tear replacement and ocular lubricant products for the treatment of dry eye syndrome are available (see the [British National Formulary](#)).

Consider topical antibiotics (e.g. chloramphenicol ointment) if there are clear signs of staphylococcal infection. Antibiotics should usually be reserved for second-line use when eyelid hygiene alone has proved ineffective<sup>5</sup>.

If clinically appropriate, medications that exacerbate dry eyes should be reviewed, e.g. topical and systemic antihistamines, tricyclic antidepressants, selective serotonin reuptake inhibitors<sup>12</sup>, diuretics, beta-blockers, isotretinoin, and possibly anxiolytics and anti-psychotics<sup>19</sup>.

### 4.3 Severe symptoms

Ulcers or other signs of corneal damage<sup>4</sup>, or secondary complications (vascularisation, corneal scarring, melt, or infections)<sup>20</sup> should be investigated by an ophthalmologist prior to prescribing such treatments as acetylcysteine eye drops or ciclosporin eye drops<sup>6</sup>.

Acetylcysteine eye drops may be considered for people with visible strands of mucus. The patient should be informed that these may sting briefly when first administered<sup>4</sup>.

Ciclosporin (Ikervis<sup>®</sup>) is recommended by the National Institute for Health and Care Excellence (NICE) as an option, within its marketing authorisation, for treating severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes<sup>21</sup>. Response to treatment should be reassessed at least every 6 months<sup>22</sup>. These reviews and any advice to discontinue therapy should be carried out by a corneal/external eye disease specialist in secondary care<sup>6</sup>.

### 4.4 Preservative toxicity from eye lubricants

In a patient with mild dry eye, preserved drops are often well tolerated when used 4–6 times a day or less<sup>1,19</sup>. However, for patients with moderate to severe dry eye syndrome, the absence of preservatives in the ocular lubricant is of more critical importance than the particular polymeric agent used<sup>1</sup>. The ocular surface inflammation associated with dry eye syndrome is exacerbated by preserved lubricants and, if patients have more than one eye condition for which they are using eye treatments, their potential exposure to preservatives is increased<sup>19</sup>. The preservative that most often causes eye irritation is benzalkonium chloride (BAK)<sup>4</sup>.

Preservative-free formulations are appropriate for patients with:

- true preservative allergy<sup>19</sup>;
- evidence of epithelial toxicity from preservatives<sup>19</sup>;
- severe dry eye with ocular surface disease and impairment of lacrimal gland secretion<sup>1</sup>;
- chronic eye disease who are on multiple preserved topical medications<sup>1</sup>;
- a prolonged daily frequency of administration greater than 6 times a day<sup>4</sup>;
- soft<sup>23</sup> or hybrid contact lens wearers.

Hypromellose, carbomers, polyvinyl alcohol, sodium chloride, carmellose sodium, hydroxyethylcellulose, and sodium hyaluronate are available without preservatives<sup>4</sup>.

### 4.5 Eye drop dispensers

It is important that patients are able to use their eye drops regularly. For those patients who encounter difficulties in administering their eye drops, consider recommending the use of a drop-aid device to aid self-instillation of their eye drops. These are particularly useful for the elderly, visually impaired, arthritic or otherwise physically limited patients. If dexterity is an issue, individual consultation with the patient about use should be considered.

## 5.0 FURTHER RESOURCES

Further information around the diagnosis and management of dry eye syndrome is available via:

- [Clinical Knowledge Summary \(CKS\) NICE – Dry eye syndrome](#)
- [Tear Film & Ocular Surface Society – MGD Report](#)
- [Tear Film & Ocular Surface Society – Report of the International Dry Eye Workshop \(DEWS\)](#)
- [The College of Optometrists – Dry Eye \(Keratoconjunctivitis Sicca, KCS\)](#)

Useful patient information is available at:

- [NHS Choices](#) – Information on dry eye syndrome and self-help techniques, including eyelid hygiene
- [Patient Dry eye information leaflet](#) (2014) – Information on how dry eye syndrome is diagnosed, complications of dry eye, and treatment with eye drops
- [Understanding Dry Eye](#) (2015) – Produced by The Royal College of Ophthalmologists and Royal National Institute of Blind People. Contains information on diagnosis, treatment, living with dry eye, and useful contacts.

## DRAFT FOR AWMSG ENDORSEMENT

### REFERENCES

1. International Dry Eye Workshop (DEWS). Report of the International Dry Eye Workshop. *The Ocular Surface*. 2007;5(2):65-204. Available at: <http://www.tearfilm.org/dewsreport/pdfs/TOS-0502-DEWS-noAds.pdf>. Accessed October 2016.
2. Drug and Therapeutics Bulletin. Clinical Review. The management of dry eye. *The British Medical Journal*. 2016;353:i2333. Available at: <http://www.bmj.com/content/353/bmj.i2333>. Accessed October 2016.
3. Nichols KK. The International Workshop on Meibomian Gland Dysfunction: Introduction. *Investigative Ophthalmology & Visual Science*. 2011;52(4):1917-1921. Available at: <http://iovs.arvojournals.org/article.aspx?articleid=2126251>. Accessed August 2016.
4. National Institute for Health and Care Excellence. Clinical Knowledge Summaries - Dry eye syndrome. 2012. Available at: <http://cks.nice.org.uk/dry-eye-syndrome>. Accessed May 2016.
5. National Institute for Health and Care Excellence. Clinical Knowledge Summaries: Blepharitis. 2015. Available at: <http://cks.nice.org.uk/blepharitis>. Accessed May 2016.
6. Aneurin Bevan University Health Board. Dry Eye Management Guidelines. 2016. Available at: <http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48819>. Accessed July 2016.
7. Evans K, and Madden L. Recommending dry eye treatments in community pharmacy. *The Pharmaceutical Journal*. 2016. Available at: <http://www.pharmaceutical-journal.com/learning/learning-article/recommending-dry-eye-treatments-in-community-pharmacy/20201430.article>. Accessed August 2016.
8. Nichols KK, Foulks GN, Bron AJ et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. *Investigative Ophthalmology & Visual Science*. 2011;52(4):1922-1929. Available at: <http://iovs.arvojournals.org/article.aspx?articleid=2126267>. Accessed June 2016.
9. National Institute for Health and Care Excellence. Medtech innovation briefing (MIB) 29: LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands. April 2015. Available at: <https://www.nice.org.uk/advice/mib29>. Accessed June 2016.
10. Northern Ireland Formulary. Health and Social Care Board. Prescribing Guidelines for Dry Eye Management. 2016. Available at: <http://niformulary.hscni.net/Formulary/Adult/11.0/11.8.1a/Pages/default.aspx>. Accessed October 2016.
11. National Health Service. NHS choices. Dry eye syndrome – Self-help. 2016. Available at: <http://www.nhs.uk/Conditions/Dry-eye-syndrome/Pages/Prevention.aspx>. Accessed October 2016.
12. All Wales Medicines Strategy Group. All Wales Choose Pharmacy Formulary. 2015. Available at: <http://www.awmsg.org/docs/awmsg/medman/All%20Wales%20Choose%20Pharmacy%20Formulary.pdf>. Accessed May 2016.
13. Kenny T, and Harding M. Dry Eyes. 2014. Available at: <http://patient.info/health/dry-eyes-leaflet>. Accessed October 2016.
14. Blackie CA, Solomon JD, Greiner JV et al. Inner eyelid surface temperature as a function of warm compress methodology. *Optometry & Vision Science*. 2008;85(8):675-683. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18677234>. Accessed June 2016.
15. Bitton E, Lacroix Z, and Léger S. In-vivo heat retention comparison of eyelid warming masks. *Contact Lens & Anterior Eye* 2016;39(4):311-315. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27162126>. Accessed August 2016.

## DRAFT FOR AWMSG ENDORSEMENT

16. Royal Pharmaceutical Society, and Centre for Pharmacy Postgraduate Education. How can you encourage medicines optimisation to improve eye health? 2016. Available at: <http://www.rpharms.com/promoting-pharmacy-pdfs/eye-health-mo-article.pdf>. Accessed May 2016.
17. Royal College of Ophthalmologists, and Royal National Institute of Blind People. Understanding Dry Eye. 2015. Available at: [https://www.rcophth.ac.uk/wp-content/uploads/2015/04/Understanding-Dry-eye\\_final.pdf](https://www.rcophth.ac.uk/wp-content/uploads/2015/04/Understanding-Dry-eye_final.pdf). Accessed November 2016.
18. British Medical Association, and Royal Pharmaceutical Society of Great Britain. British National Formulary. May 2016. Available at: <https://www.medicinescomplete.com/mc/bnf/current/>.
19. 3Ts Formulary. Prescribing guidance for dry eye syndrome. 2016. Available at: [http://www.gwh.nhs.uk/media/236295/3ts-prescribing-guidelines-for-dry-eye-syndrome\\_sept2016\\_v4.pdf](http://www.gwh.nhs.uk/media/236295/3ts-prescribing-guidelines-for-dry-eye-syndrome_sept2016_v4.pdf). Accessed May 2016.
20. The College of Optometrists. Dry Eye (Keratoconjunctivitis Sicca) (KCS). 2015. Available at: <http://www.college-optometrists.org/en/utilities/document-summary.cfm/docid/4111ACA3-058B-45B5-ADDFC10FF163263D>. Accessed October 2016.
21. National Institute for Health and Care Excellence. Technology Appraisal 369. Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears. December 2015. Available at: <https://www.nice.org.uk/guidance/ta369>. Accessed May 2016.
22. Santen UK Limited. Ikervis<sup>®</sup> 1 mg/ml eye drops, emulsion . Summary of Product Characteristics. 2016. Available at: <https://www.medicines.org.uk/emc/medicine/30584>. Accessed October 2016.
23. National Health Service. Dry eye syndrome – Treatment. 2016. Available at: <http://www.nhs.uk/Conditions/Dry-eye-syndrome/Pages/Treatment.aspx>. Accessed October 2016.